Patents by Inventor Roger M. Freidinger

Roger M. Freidinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6544982
    Abstract: A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: April 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Harold G. Selnick, Philippe G. Nantermet, James C. Barrow, Roger M. Freidinger, Thomas Connolly
  • Patent number: 6090805
    Abstract: This invention relates to certain novel benzoxazinone compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: July 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Peter D. Williams, Michelle A. Sparks, Ian Bell, Debra S. Perlow, Kenneth Stauffer, Roger M. Freidinger
  • Patent number: 6075038
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral fining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: June 13, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Michael A. Patane, Mark G. Bock, Roger M. Freidinger
  • Patent number: 5977115
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: November 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Michael A. Patane, Mark G. Bock, Roger M. Freidinger, Rose Ann Ponticello, Randall C. Newton
  • Patent number: 5968938
    Abstract: This invention relates to certain novel piperazine compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: October 19, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Peter D. Williams, Michelle A. Sparks, Ian Bell, James P. Guare, Jr., Roger M. Freidinger
  • Patent number: 5834464
    Abstract: Imidazolinobenzodiazepines are cholecystokinin B (CCK-B) antagonists useful as anxiolytic agents.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: November 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Robert M. DiPardo, Roger M. Freidinger
  • Patent number: 5756497
    Abstract: This invention relates to certain novel benzoxazinone compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor in mammals, especially humans. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Roger M. Freidinger, Peter D. Williams
  • Patent number: 5726172
    Abstract: This invention relates to certain novel benzoxazinone compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: March 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Michelle A. Sparks, Roger M. Freidinger, Debra S. Perlow, Peter D. Williams
  • Patent number: 5714485
    Abstract: Compounds of the invention have the following structure: ##STR1##
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: February 3, 1998
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Roger M. Freidinger, Stephen F. Brady, Philip E. Sanderson, Dong-Mei Feng, Terry A. Lyle, Kenneth J. Stauffer, Thomas J. Tucker, Joseph P. Vacca
  • Patent number: 5691331
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • Patent number: 5691332
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • Patent number: 5665719
    Abstract: Compounds of the formula ##STR1## X is --O--, --NH-- and --NR.sup.8 --; Y is --CH.sub.2 --, --CHR.sup.8 -- and --C(R.sup.8).sub.2 --; R.sup.1 is camphor-10-yl, C.sub.1-5 alkoxyl, styryl, hydroxystyryl, furyl, unsubstituted or substituted thienyl, naphthyl, indolyl, tetrahydronaphthyl, unsubstituted, mono- or di-substituted pyridyl, pyrazinyl, unsubstituted or substituted cyclohexyl where the substituent is R.sup.4, and unsubstituted or substituted phenyl where the substituents on phenyl are R.sup.5, R.sup.6 and R.sup.7 ; R.sup.2 is hydrogen, C.sub.1-5 alkoxy, C.sub.1-5 alkyl, amino, C.sub.1-5 alkylcarbonylamino, nitro or halogen; R.sup.3 is hydrogen, C.sub.1-5 alkoxycarbonyl, cyano or carbamoyl; R.sup.4 is one to two of hydrogen, oxo, hydroxy, C.sub.1-5 alkoxy, C.sub.1-5 alkoxycarbonylamino-C.sub.1-5 alkyl and amino-C.sub.1-5 alkyl; R.sup.5, R.sup.6 are each independently selected from hydrogen, halogen, C.sub.1-5 alkyl, hydroxyl and C.sub.1-5 alkoxy; R.sup.7 is ##STR2## W is CO or SO.sub.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 9, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Peter D. Williams, Roger M. Freidinger, Douglas J. Pettibone, Doug W. Hobbs, Paul S. Anderson
  • Patent number: 5661163
    Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 26, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Michael A. Patane, Mark G. Bock, Roger M. Freidinger, Rose Ann Ponticello
  • Patent number: 5510369
    Abstract: Compounds of the invention have the following structure: ##STR1## for example ##STR2## These compounds inhibit thrombin and associated thrombosis.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: April 23, 1996
    Assignee: Merck & Co., Inc.
    Inventors: William C. Lumma, Roger M. Freidinger, Stephen F. Brady, Philip E. Sanderson, Dong-Mei Feng, Terry A. Lyle, Kenneth J. Stauffer, Thomas J. Tucker, Joseph P. Vacca
  • Patent number: 5439906
    Abstract: Imidazobenzo-(1,5)-diazepine derivatives with an amide or urea function in the 3-position are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: August 8, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Robert M. DiPardo, Roger M. Freidinger, John J. Baldwin, David C. Remy
  • Patent number: 5378838
    Abstract: Benzodiazepine analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: January 3, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey M. Bergman, Roger M. Freidinger, Mark G. Bock
  • Patent number: 5356904
    Abstract: A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; R.sup.
    Type: Grant
    Filed: October 7, 1992
    Date of Patent: October 18, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Joseph M. Pawluczyk, Douglas J. Pettibone, Peter D. Williams
  • Patent number: 5324726
    Abstract: Benzodiazepine analogs of the formula: ##STR1## wherein: R.sup.3 is ##STR2## --NH(CH.sub.2).sub.2 --.sub.3 NHCOR.sup.7, ##STR3## or --X.sup.11 NR.sup.18 SO.sub.2 (CH.sub.2).sub.q R.sup.7 ; R.sup.7 is O,S,HH, or NR.sup.15 with the proviso that X.sup.7 can be NR.sup.15 only when R.sup.1 is not H.are disclosed which are antagonists of gastrin and cholecystokinin (CCK) with enhanced aqueous solubility and have properties useful in the treatment of disorders of gastric secretion, appetite regulation, gastrointestinal motility, pancreatic secretion, and dopaminergic function, as well as in treatment producing potentiation of morphine and other opiate analgesics.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: June 28, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger
  • Patent number: 5225528
    Abstract: Disclosed are cyclic hexapeptides of the formula: ##STR1## These compounds are antagonists of oxytocin and are useful in the treatment of preterm labor and dysmenorrhea, and for stoppage of labor prepatory to Caesarian delivery. Also disclosed are pharmaceutical compositions containing the compounds of formula I and methods of preparing these compounds.
    Type: Grant
    Filed: December 17, 1990
    Date of Patent: July 6, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Roger M. Freidinger, Roger D. Tung, Daniel F. Veber, Peter D. Williams
  • Patent number: 5220018
    Abstract: Benzodiazepine analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: June 15, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Roger M. Freidinger